AN2 Therapeutics reports positive efficacy data for Chagas disease candidate
AN2 Therapeutics (NASDAQ:ANTX) announced positive data today from two separate studies evaluating its investigational oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease—a parasitic condition caused by Trypanosoma cruzi that affects millions globally.










